See the DrugPatentWatch profile for Eylea
Who makes Eylea—Bayer or Regeneron?
Eylea is an eye drug developed and sold by Regeneron and Bayer. Bayer markets Eylea, while Regeneron is the company associated with its development. Both companies are tied to the product’s commercial presence.
Who owns the rights to Eylea and how do Bayer and Regeneron split roles?
For many Eylea-related materials and listings, the partnership is reflected as Bayer as the marketer/commercial owner in key markets and Regeneron as the biopharma partner linked to development and manufacturing.
What is Eylea used for (and why does that matter for the companies)?
Eylea is used in ophthalmology, including treatment of conditions such as wet age-related macular degeneration. The drug’s specialty, and the way it’s marketed through specialty channels, is part of why brand ownership and partnership roles stay visible in product documentation.
Is Eylea Bayer’s product or Regeneron’s product?
Eylea is generally described as a Bayer brand/marketed product created through a Regeneron partnership. That’s why you may see both names attached: Bayer for the marketed brand and Regeneron for the underlying biotech association.
How to verify the exact company listed on your local product label
If you’re looking at the exact legal holder for your country (or the prescribing information your clinic uses), check the package insert or the local label’s “manufacturer” and “marketing authorization holder” lines, since these can differ by region.
Sources:
1. DrugPatentWatch – Eylea (aflibercept)